开发抗禽流感病毒疫苗的科学障碍。
Scientific barriers to developing vaccines against avian influenza viruses.
作者信息
Subbarao Kanta, Joseph Tomy
机构信息
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
出版信息
Nat Rev Immunol. 2007 Apr;7(4):267-78. doi: 10.1038/nri2054.
Abstract
The increasing number of reports of direct transmission of avian influenza viruses to humans underscores the need for control strategies to prevent an influenza pandemic. Vaccination is the key strategy to prevent severe illness and death from pandemic influenza. Despite long-term experience with vaccines against human influenza viruses, researchers face several additional challenges in developing human vaccines against avian influenza viruses. In this Review, we discuss the features of avian influenza viruses, the gaps in our understanding of infections caused by these viruses in humans and of the immune response to them that distinguishes them from human influenza viruses, and the current status of vaccine development.
摘要
禽流感病毒直接传播给人类的报告数量不断增加，凸显了采取控制策略以预防流感大流行的必要性。接种疫苗是预防大流行性流感导致严重疾病和死亡的关键策略。尽管在针对人类流感病毒的疫苗方面有长期经验，但研究人员在开发针对禽流感病毒的人类疫苗时仍面临若干其他挑战。在本综述中，我们讨论了禽流感病毒的特征、我们对这些病毒在人类中引起的感染以及与之不同的针对它们的免疫反应的理解方面的差距，以及疫苗开发的现状。
相似文献
1
Scientific barriers to developing vaccines against avian influenza viruses.
Nat Rev Immunol. 2007 Apr;7(4):267-78. doi: 10.1038/nri2054.
2
Influenza: lessons from past pandemics, warnings from current incidents.
Nat Rev Microbiol. 2005 Aug;3(8):591-600. doi: 10.1038/nrmicro1208.
3
[Influenza, an existing public health problem].
Salud Publica Mex. 2006 May-Jun;48(3):244-67. doi: 10.1590/s0036-36342006000300009.
4
Vaccines against epidemic and pandemic influenza.
Expert Opin Drug Deliv. 2008 Oct;5(10):1139-57. doi: 10.1517/17425247.5.10.1139.
5
Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
Expert Rev Vaccines. 2007 Apr;6(2):193-201. doi: 10.1586/14760584.6.2.193.
6
Confronting the avian influenza threat: vaccine development for a potential pandemic.
Lancet Infect Dis. 2004 Aug;4(8):499-509. doi: 10.1016/S1473-3099(04)01105-3.
7
Recent developments in avian influenza research: epidemiology and immunoprophylaxis.
Vet J. 2002 Nov;164(3):202-15. doi: 10.1053/tvjl.2002.0716.
8
Genesis of pandemic influenza.
Cytogenet Genome Res. 2007;117(1-4):394-402. doi: 10.1159/000103203.
9
Influenza vaccines and vaccination strategies in birds.
Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):121-65. doi: 10.1016/j.cimid.2007.07.004. Epub 2007 Sep 24.
10
Development of live attenuated influenza vaccines against pandemic influenza strains.
Expert Rev Vaccines. 2014 Jul;13(7):855-71. doi: 10.1586/14760584.2014.922417. Epub 2014 May 28.
引用本文的文献
1
Synthetic biology-inspired development of live attenuated influenza vaccines.
NPJ Vaccines. 2025 Aug 27;10(1):204. doi: 10.1038/s41541-025-01255-1.
2
Characteristics and evolution of hemagglutinin and neuraminidase genes of Influenza A(H3N2) viruses in Thailand during 2015 to 2018.
PeerJ. 2024 Jun 3;12:e17523. doi: 10.7717/peerj.17523. eCollection 2024.
3
A Universal Aptamer for Influenza A Viruses: Selection, Recognition, and Infection Inhibition.
ACS Pharmacol Transl Sci. 2023 Dec 29;7(1):249-258. doi: 10.1021/acsptsci.3c00258. eCollection 2024 Jan 12.
4
Identification of the Imidazo[1,2-]pyrazine Derivative as a Potential Influenza Virus Nucleoprotein Inhibitor.
ACS Pharmacol Transl Sci. 2023 Nov 17;6(12):1841-1850. doi: 10.1021/acsptsci.3c00174. eCollection 2023 Dec 8.
5
Modification of surface glycan by expression of beta-1,4-N-acetyl-galactosaminyltransferase (B4GALNT2) confers resistance to multiple viruses infection in chicken fibroblast cell.
Front Vet Sci. 2023 Jul 6;10:1160600. doi: 10.3389/fvets.2023.1160600. eCollection 2023.
6
Roles and Mechanisms of NLRP3 in Influenza Viral Infection.
Viruses. 2023 Jun 8;15(6):1339. doi: 10.3390/v15061339.
7
Immune Control of Avian Influenza Virus Infection and Its Vaccine Development.
Vaccines (Basel). 2023 Mar 4;11(3):593. doi: 10.3390/vaccines11030593.
8
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.
NPJ Vaccines. 2022 Aug 30;7(1):103. doi: 10.1038/s41541-022-00524-7.
9
Progress towards the Development of a Universal Influenza Vaccine.
Viruses. 2022 Jul 30;14(8):1684. doi: 10.3390/v14081684.
10
Screening and purification of NanB sialidase from Pasteurella multocida with activity in hydrolyzing sialic acid Neu5Acα(2-6)Gal and Neu5Acα(2-3)Gal.
Sci Rep. 2022 Jun 8;12(1):9425. doi: 10.1038/s41598-022-13635-x.
本文引用的文献
1
Emerging respiratory viruses: challenges and vaccine strategies.
Clin Microbiol Rev. 2006 Oct;19(4):614-36. doi: 10.1128/CMR.00005-06.
2
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
Clin Infect Dis. 2006 Nov 1;43(9):1135-42. doi: 10.1086/508174. Epub 2006 Sep 25.
3
Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.
J Infect Dis. 2006 Oct 15;194(8):1040-3. doi: 10.1086/507709. Epub 2006 Sep 12.
4
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
Lancet. 2006 Sep 16;368(9540):991-7. doi: 10.1016/S0140-6736(06)69294-5.
5
H5N1 vaccines: how prepared are we for a pandemic?
Lancet. 2006 Sep 16;368(9540):965-6. doi: 10.1016/S0140-6736(06)69340-9.
6
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
PLoS Med. 2006 Sep;3(9):e360. doi: 10.1371/journal.pmed.0030360.
7
Evidence of a cross-protective immune response to influenza A in the cotton rat model.
Vaccine. 2006 Sep 11;24(37-39):6264-71. doi: 10.1016/j.vaccine.2006.05.092. Epub 2006 Jun 13.
8
The guinea pig as a transmission model for human influenza viruses.
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9988-92. doi: 10.1073/pnas.0604157103. Epub 2006 Jun 19.
9
Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
J Infect Dis. 2006 Jul 15;194(2):159-67. doi: 10.1086/505225. Epub 2006 Jun 9.
10
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.
Lancet. 2006 May 20;367(9523):1657-64. doi: 10.1016/S0140-6736(06)68656-X.
Zotero 插件